aap Implantate announced that it successfully completed its transformation to a pure trauma player in 2016. The company reported challenging FY16 results that were below management’s original expectations, but broadly in line with the revised guidance, with sales from its continuing operations down 15% y-o-y to €10.5m. However, this was not wholly unexpected as the company has undergone a strategic transition to being a pure trauma-focused company. Increasing market penetration in
06 Apr 2017
Time to capitalise on its core focus - trauma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Time to capitalise on its core focus - trauma
aap Implantate AG (AAQ1:ETR) | 0 0 5.5% | Mkt Cap: 50.5m
- Published:
06 Apr 2017 -
Author:
Dr Linda Pomeroy -
Pages:
2
aap Implantate announced that it successfully completed its transformation to a pure trauma player in 2016. The company reported challenging FY16 results that were below management’s original expectations, but broadly in line with the revised guidance, with sales from its continuing operations down 15% y-o-y to €10.5m. However, this was not wholly unexpected as the company has undergone a strategic transition to being a pure trauma-focused company. Increasing market penetration in